Importantly, the WHO classification categorizes the specific fusion gene MLL-AF9 as an entity and recommends that the partners in the variant MLL fusion genes should be identified; however, MLL-AF9 is one of the most common fusion gene presented in patients with AML (10, 11). This evidence concerns the gene KMT2A and acute myeloid leukemia.